🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Adding either FOF or TOB to C/T at simulated human clinically observed concentrations reduced P. aeruginosa bacterial loads & the risk of C/T resistance when strains had C/T MICs at or above the clinical breakpoint: doi.org/10.1093/jac/dk… Marie L G Attwood @OUPMedicine #JACNews

Thanks everyone who came to the enjoyable + thought provoking 13th Oxford Phage Meeting. This was my concluding remarks - showing how the talks mapped to the which phages to use, how many and how will they interact with their environment. lpmhealthcare.com/phages-2023/ #PhgOx23

It’s out! 🥳🧫⚡️💧💜 We show that #ColdPlasma #PAW can be used as an effective pre-treatment strategy for #biofilm infected #ChronicWounds. We also suss out some of the mechanisms underpinning PAWs antimicrobial/anti-biofilm activity 💪🏽 🌟

My latest article: Exposure of Escherichia coli to antibiotic-efflux pump inhibitor combinations in a pharmacokinetic model: impact on bacterial clearance and drug resistance. Great collaboration with Tim Opperman and Alasdair MacGowan 🙂 academic.oup.com/jac/advance-ar…

biorxiv.org/content/10.110…

Publishing a paper in a relatively decent journal

Our research Martha Clokie is available on ResearchGate: researchgate.net/publication/38…

Please look at the latest research produced by the pK/pD lab, Bristol ResearchGate: researchgate.net/publication/38…

linkedin.com/posts/marie-at…

Check out our latest work from Bristol in collaboration with the University of Liverpool, Athens, Patras and Micron Ltd - Population pK/pD of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA academic.oup.com/jac/article-ab…

Two videos today for our series on the ESCMID/ASM Conference 2024: Alasdair MacGowan presents two works on treatments against Acinetobacter baumannii and NDM producing Escherichia coli. 📺📺 ow.ly/OmQI50Tm0Fx 📺📺

Why BeckyMayerCentreforPhageResearch - alongside our phage colleagues globally, are doing the work we do articulated in 30 seconds!

Dear network, I am happy to announce the launch of our LinkedIn page for the PhageCompass Consortium, a global collaboration dedicated to advancing the future of bacteriophage therapy, discovery, and education. From developing cutting-edge tools for genomic prediction to

Our latest collaboration, #GNANOW researchgate.net/publication/38…

Find our latest manuscript collaboration. Its been a pleasure working on this project ://www.researchgate.net/publication/388566335_The_pharmacodynamics_of_fosfomycin_in_combination_with_meropenem_against_Klebsiella_pneumoniae_studied_in_an_in_vitro_model_of_infection

📣📣 Grand Challenge announced 👇🏻: Innovations for Gram-Negative Antibiotic Discovery gcgh.grandchallenges.org/challenge/inno…

Please check out the lasted work driven by Yojana Gadiya et al research . Available on ResearchGate: researchgate.net/publication/38…

A privilege to present our work from the PKPD lab , NBT NHS Trust Bristol at ESCMID global

At GARDP, we’re changing the way #antibiotics are developed and accessed by 🛡️ Protecting adults from serious bacterial infections 👶 Helping newborns fight sepsis 💊 Treating drug-resistant gonorrhoea 🌍 Overcoming access barriers 🔬 Advancing new antibiotic discoveries

💥Drug resistance is rising, yet new antibiotics aren’t keeping pace – putting millions at risk. GARDP is flipping the traditional R&D model by prioritizing high-burden countries, targeting drug-resistant infections and ensuring access from day one. THIS IS BIG: